Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.35 |
| ▸ | CA2 | P00918 | 4/20 | 0.35 |
| ▸ | CA9 | Q16790 | 4/20 | 0.35 |
| ▸ | CA7 | P43166 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15721047 | 1.00 | CA1 (0.35) | CA1CA2CA9CA7TSHR | |
| SCHEMBL4619157 | 1.00 | CA1 (0.35) | CA1CA2CA9CA7TSHR | |
| SCHEMBL4619145 | 1.00 | CA1 (0.35) | CA1CA2CA9CA7TSHR | |
| SCHEMBL14747277 | 0.97 | CA1 (0.35) | CA1CA2CA9CA7TSHR | |
| SCHEMBL14747292 | 0.97 | CA1 (0.35) | CA1CA2CA9CA7TSHR | |
| SCHEMBL754270 | 0.97 | CA1 (0.35) | CA1CA2CA9CA7TSHR | |
| SCHEMBL9344087 | 0.97 | CA1 (0.35) | CA1CA2CA9CA7TSHR | |
| SCHEMBL14372181 | 0.97 | CA1 (0.35) | CA1CA2CA9CA7TSHR | |
| SCHEMBL15892827 | 0.89 | CA1 (0.42) | CA1CA2CA9CA7TSHR | |
| SCHEMBL9850496 | 0.85 | KMT2A (0.42) | CA1CA2CA9CA7TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9199935-B2 | Pharmaceutically active piperidine derivatives | Acetelion Pharmaceuticals Ltd. (CH) | 2015-12-01 | — | — | US | disclosed |
| US-20140303208-A1 | PHARMACEUTICALLY ACTIVE PIPERIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-10-09 | — | — | US | disclosed |
| US-8729099-B2 | Pharmaceutically active piperidine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-05-20 | — | — | US | disclosed |
| US-8729099-B2 | Pharmaceutically active piperidine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-05-20 | — | — | US | disclosed |
| US-7994198-B2 | Piperidinetriol derivatives as inhibitors of glycosylceramidsynthase | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-08-09 | — | — | US | disclosed |
| EP-1362031-B1 | PHARMACEUTICALLY ACTIVE PIPERIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-03-19 | — | — | EP | disclosed |
| US-20070259918-A1 | 2-Hydroxymethyl-3,4,5-Trihydroxy-1-(4-Pentyloxybenzyl) Piperidine as Glucosylceramide Synthase (Gcs) Inhibitor | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-11-08 | — | — | US | disclosed |
| US-20060074107-A1 | Pharmaceutically active piperidine derivatives | OXFORD GLYCOSCIENCES (UK) LTD. | 2006-04-06 | — | — | US | disclosed |
| US-20040097551-A1 | As inhibitors of glucosylceramide synthase; for therapy and prophylaxis | OXFORD GLYCOSCIENCES (UK) LTD. (GB) | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303208-A1 | PHARMACEUTICALLY ACTIVE PIPERIDINE DERIVATIVES | GBA1, GBA2, UGCG | CA1 3355/4885CA2 2788/4885CA9 1969/4885 |
| US-20070259918-A1 | 2-Hydroxymethyl-3,4,5-Trihydroxy-1-(4-Pentyloxybenzyl) Piperidine as Glucosylceramide Synthase (Gcs) Inhibitor | UGCG, CERS2, GBA1 | CA1 2239/4885CA2 1626/4885CA9 2301/4885 |
| US-20060074107-A1 | Pharmaceutically active piperidine derivatives | GBA1, GBA2, UGCG | CA1 3355/4885CA2 2788/4885CA9 1969/4885 |
| US-20040097551-A1 | As inhibitors of glucosylceramide synthase; for therapy and prophylaxis | GBA1, UGCG, GBA2 | CA1 1775/4885CA2 2864/4885CA9 1777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.